Chief Operating Officer and Interim CEO
United States of America
Joseph Lobacki is Crestovo’s chief operating officer and interim chief executive officer. Prior to Crestovo, Mr. Lobacki was chief commercial officer at Medivation, which was acquired by Pfizer in September 2016. Previously, Mr. Lobacki served as the general manager of the oncology business at Idera Pharmaceuticals, senior vice president and chief commercial officer at Micromet Inc., senior vice president and general manager of transplant and oncology at Genzyme Corporation, vice president of North American marketing at SangStat Medical Corporation and vice president of operations of Cell Pathways, Inc. Mr. Lobacki holds a B.S. in biology from Boston College and a B.S. in pharmacy from Massachusetts College of Pharmacy.
Clinical-stage biopharmaceutical company, developing and delivering innovative therapies, human gut microbiome, orally-administered, full-spectrum bacterial composition products, Clostridium difficile infection (CDI)